TRDA
NASDAQ HealthcareEntrada Therapeutics, Inc. - Common Stock
Biotechnology
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $13.99 |
|---|---|
| 成交量 | 111,209 |
| 市值 | 535.60M |
| 贝塔系数 | -0.150 |
| RSI（14日） | 68.1 |
| 200日均线 | $8.86 |
| 50日均线 | $12.28 |
| 52周最高 | $14.49 |
| 52周最低 | $4.93 |
| Forward P/E | -4.06 |
| Price / Book | 1.65 |
🎯 投资策略评分
TRDA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 💰 Dividend Daddy (50/100) — 此策略 高股息率 + 低波动性.
评分最低的策略： 🚀 Moon Shot (5/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 TRDA in your text
粘贴任何文章、记录或帖子 — 工具将提取 TRDA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.